Renaissance Capital logo

IO Biotech Priced, Nasdaq: IOBT

Phase 3-ready biotech developing immunotherapies for melanoma and other cancers.

Industry: Health Care

Latest Trade: $1.15 0.00 (0.0%)

First Day Return: +11.8%

Return from IPO: -91.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform. Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. We believe this represents a paradigm shift in the management of cancer and that our product candidates have the potential to become cornerstones of the treatment regimens of multiple solid tumors. Our lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death ligand (PD-L1). In a single-arm Phase 1/2 clinical trial (the MM1636 trial) of 30 patients with metastatic melanoma with the primary objective to investigate safety and tolerability, secondary objective to investigate immunogenicity and tertiary objective to investigate clinical efficacy, IO102-IO103, in combination with nivolumab, demonstrated an ability to induce meaningful tumor regression and establish durable antitumor response while achieving a manageable tolerability profile for patients.
more less
IPO Data
IPO File Date 10/15/2021
Offer Price $14.00
Price Range $14.00 - $17.00
Offer Shares (mm) 7.2
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/04/2021
Offer Price $14.00
Price Range $14.00 - $17.00
Offer Shares (mm) 7.2
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
Jefferies
more
Company Data
Headquarters Copenhagen, Denmark
Founded 2014
Employees at IPO 19
Website www.iobiotech.com

IO Biotech (IOBT) Performance